{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:23:02Z","timestamp":1791062582820,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,13]]},"abstract":"<jats:p>Kaposi sarcoma (KS) is the most common cancer in patients with human immunodeficiency virus\/acquired immunodeficiency syndrome (AIDS). In 1994, Chang and Moore discovered Kaposi sarcoma associated herpesvirus for the first time in KS lesions in AIDS patients. KS is a low-grade mesenchymal neoplasm of blood and lymphatic vessels that primarily affects the skin, although the disease may become disseminated to the lymphatic system, lungs, airways, or abdominal viscera. In this research, clinical characteristics and treatment of patients of Kaposi sarcoma were retrospectively analyzed in Hotan District, Xinjiang China. We look into the clinical traits, prognosis, and therapy of Kaposi sarcoma. From May 2017 to August 2022, 32 patients were treated in the People\u2019s Hospital of Hotan District, Xinjiang Uygur Autonomous Region, China. Twenty-two of these were classic Kaposi sarcomas (cKS), and 10 of these were Kaposi sarcomas linked to AIDS (AIDS-KS). The majority of KS patients were Uyghur. In terms of age at onset, AIDS-KS patients were younger than cKS patients. cKS and AIDS-KS are most frequently manifested in the feet and lower limbs. Ten patients with AIDS-KS have treated with combination antiretroviral therapy (combination antiretroviral therapy) combination chemotherapy, 5 of 10 patients had a complete response, 2 patients achieved partial response, the overall effective rate was 70%, and CD4 + T cells were greater than before. For cKS and AIDS-KS, the median overall survival was 56 and 50.8 months, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; .05). As a result, antiviral combination chemotherapy can also improve the prognosis of AIDS-KS patients.<\/jats:p>","DOI":"10.1097\/md.0000000000035552","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:03:02Z","timestamp":1697230982000},"page":"e35552","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["A retrospective study of Kaposi\u2019s sarcoma in Hotan region of Xinjiang, China"],"prefix":"10.1097","volume":"102","author":[{"given":"Hong Liang","family":"Yang","sequence":"first","affiliation":[{"name":"Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China"},{"name":"Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin\u2019s Clinical Research Center for Cancer, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"He","sequence":"additional","affiliation":[{"name":"Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aibibai","family":"Jielili","sequence":"additional","affiliation":[{"name":"Department of Oncology, People\u2019s Hospital of Hotan District, Xinjiang Uygur Autonomous Region, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Rong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, People\u2019s Hospital of Hotan District, Xinjiang Uygur Autonomous Region, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Yong","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Oncology, People\u2019s Hospital of Hotan District, Xinjiang Uygur Autonomous Region, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, People\u2019s Hospital of Hotan District, Xinjiang Uygur Autonomous Region, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai Tao","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Oncology, People\u2019s Hospital of Hotan District, Xinjiang Uygur Autonomous Region, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/cncr.25547","article-title":"Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States.","volume":"117","author":"Simard","year":"2011","journal-title":"Cancer"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1002\/cncr.27410","article-title":"Cancer burden in Africa and opportunities for prevention.","volume":"118","author":"Jemal","year":"2012","journal-title":"Cancer"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/archinte.1996.00440020112014","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus and Kaposi\u2019s sarcoma in Africa. Uganda Kaposi\u2019s sarcoma study group.","volume":"156","author":"Chang","year":"1996","journal-title":"Arch Intern Med"},{"key":"R4-20250504","first-page":"199","article-title":"Update on Kaposi sarcoma-associated herpesvirus (KSHV or HHV8)-review.","volume":"58","author":"Iftode","year":"2020","journal-title":"Rom J Intern Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1016\/j.vaccine.2019.04.071","article-title":"A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits.","volume":"37","author":"David","year":"2019","journal-title":"Vaccine"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2018.12.036","article-title":"Diagnosis and treatment of Kaposi\u2019s sarcoma: European consensusbased interdisciplinary guideline (EDF\/EADO\/EORTC).","volume":"114","author":"Celeste","year":"2019","journal-title":"Eur J Cancer"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1399-0039.1995.tb02427.x","article-title":"HLA in familial and nonfamilial Mediterranean Kaposi\u2019s sarcoma in Greece.","volume":"45","author":"Kaloterakis","year":"1995","journal-title":"Tissue Antigens"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1038\/s41598-019-41218-w","article-title":"Human herpesvirus infections and dementia or mild cognitive impairment: a systematic review and meta-analysis.","volume":"9","author":"Charlotte","year":"2019","journal-title":"Sci Rep"},{"key":"R9-20250504","first-page":"E11379","article-title":"Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus.","volume":"115","author":"Rachele","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/ijd.14080","article-title":"Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant.","volume":"58","author":"Vangipuram","year":"2019","journal-title":"Int J Dermatol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jdv.12349","article-title":"One hundred and five Kaposi sarcoma patients: a clinical study in Xinjiang, Northwest of China.","volume":"28","author":"Wu","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2008.05.001","article-title":"Kaposi sarcoma: a continuing conundrum.","volume":"59","author":"Schwartz","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/CCO.0000000000000601","article-title":"Update on oncogenesis and therapy for Kaposi sarcoma.","volume":"32","author":"Dupin","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/infdis\/jiu667","article-title":"2015 Whole-genome sequencing identifies STAT4 as a putative susceptibility gene in classic Kaposi sarcoma.","volume":"211","author":"Mervi","year":"2015","journal-title":"J Infect Dis"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/QAD.0000000000002744","article-title":"A comparative study of classic and HIV-viremic and aviremic AIDS Kaposi sarcoma.","volume":"35","author":"David","year":"2021","journal-title":"AIDS"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1158\/1078-0432.CCR-18-3528","article-title":"A pilot study of liposomal doxorubicin combined with bevacizumab followed by bevacizumab monotherapy in patients with advanced Kaposi Sarcoma.","volume":"25","author":"Ramya","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/apc.2013.0184","article-title":"Interferon therapy for Kaposi sarcoma associated with acquired immunodeficiency syndrome: still a valid treatment option?","volume":"27","author":"Isabelle","year":"2013","journal-title":"AIDS Patient Care STDS"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2000.18.13.2593","article-title":"Activity of thalidomide in AIDS-related Kaposi\u2019s sarcoma.","volume":"18","author":"Little","year":"2000","journal-title":"J Clin Oncol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0959-8049(01)00053-3","article-title":"Long-term chemotherapy of HIV-associated Kaposi\u2019s sarcoma with liposomal doxorubicin.","volume":"37","author":"Hengge","year":"2001","journal-title":"Eur J Cancer"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2005.04.2614","article-title":"Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi\u2019s sarcoma: an AIDS Malignancy Consortium Study.","volume":"24","author":"Bruce","year":"2006","journal-title":"J Clin Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"173","DOI":"10.6002\/ect.2017.0075","article-title":"Kaposi sarcoma after allogeneic hematopoietic stem cell transplant: a rare complication.","volume":"19","author":"Mani","year":"2021","journal-title":"Exp Clin Transplant"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:14:09Z","timestamp":1746324849000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":21,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035552","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}